Anti Mag News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Jorge J. Castillo, MD, discusses preliminary data from a phase 2 study of acalabrutinib plus rituximab in patients with IgM symptomatic anti-MAG peripheral neuropathy.

Jorgej castilloHarvard medical schoolDana farber cancer instituteBing centerOnclive tvHematologic oncologyMash 2023Waldenström macroglobulinemiaAnti magPeripheral neuropathy